Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
Chongchong Zhou,1,2,* Jingxuan Wei,1,* Kai Xu,1 Yingtao Lin,3,4 Lingli Zhang,1 Xin Li1,4,5 1Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, People’s Republic of China; 2Department of Research Management, Nanjing...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2023-11-01
|
| Collection: | Risk Management and Healthcare Policy |
| Sujets: | |
| Accès en ligne: | https://www.dovepress.com/cost-effectiveness-analysis-of-tislelizumab-plus-chemotherapy-as-first-peer-reviewed-fulltext-article-RMHP |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|